Terbinafine-induced Subacute Cutaneous Lupus Erythematosus

Clin Dermatol. 2004 Mar-Apr;22(2):157-66.

Drug-induced lupus erythematosus.

Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N.

Department of Dermatology and Venereology, Sofia Faculty of Medicine, Sofia, Bulgaria. dimitar_antonov@doctor.bg

Among the numerous idiopathic immune-mediated diseases that can be drug-induced, such as pemphigus, psoriasis, lichen, etc, drug-induced lupus is the most widely commented upon and investigated. The terms drug-induced lupus (DIL) and drug-induced lupus erythematosus (DILE) are preferred, but other ones are also used--drug-related lupus, lupus-like syndrome, and lupus erythematosus medicamentosus. This review discusses the general issues in DILE, such as pathogenic mechanisms, clinical forms, and diagnostic criteria, and provides more detailed information for some of the implicated drugs: minocycline, statins, terbinafine, etc.

Publication Types:

* Review
* Review, Tutorial

PMID: 15234017 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uid...


Acta Dermato-Venereologica
Publisher: Taylor & Francis
Issue: Volume 84, Number 6 / November 2004
Pages: 472 - 474
URL: Linking Options
DOI: 10.1080/00015550410018361

Terbinafine-induced Subacute Cutaneous Lupus Erythematosus

David A. McKay , Olivia M.V. Schofield , E. Claire Benton

A1 Department of Dermatology Royal Infirmary of Edinburgh Edinburgh UK

Abstract:

Oral terbinafine is licensed for use in onychomycosis after positive confirmation of infection. We describe five cases of subacute cutaneous lupus erythematosus associated with terbinafine therapy. All cases had positive antibodies to extractable nuclear antigens, predominantly anti-Ro, and several had a history of pre-existing autoimmune disease. Terbinafine should only be prescribed after confirmation of infection by microscopy or culture.

Keywords:

SCLE, drug-reaction, onychomycosis

http://taylorandfrancis.metapress.com/app/home/contribution.asp?wasp=de4d22bf...


Terbinafine-induced subacute cutaneous lupus erythematosus.

Bonsmann G, Schiller M, Luger TA, Stander S.

Department of Dermatology, University of Munster, Germany. bonsmag@uni-muenster.de

BACKGROUND: Recently, the induction of subacute cutaneous lupus erythematosus (SCLE) and exacerbation of systemic lupus erythematosus by terbinafine have been reported.

CONCLUSION: Terbinafine is a drug that appears to infrequently induce SCLE with high titers of ANAs and anti-histone antibodies in genetically susceptible persons.

Publication Types:

* Case Reports
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&...

Arch Dermatol. 2001 Sep;137(9):1196-8

Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine
Callen JP, Hughes AP, Kulp-Shorten C.

Division of Dermatology, Department of Medicine, University of Louisville, 310 E Broadway, Suite 200, Louisville, KY 40202, USA. jefca@aol.com

BACKGROUND: Subacute cutaneous lupus erythematosus is a nonscarring, non-atrophy-producing photosensitive cutaneous disorder. Half of the patients have 4 or more of the criteria for classification as systemic lupus erythematosus. In some patients, drugs induce or exacerbate the cutaneous disease. OBSERVATION: We describe 5 patients who had either an exacerbation or a new onset of subacute cutaneous lupus erythematosus while taking terbinafine for presumed onychomycosis. CONCLUSION: In general, terbinafine is a safe drug, but perhaps patients with known lupus erythematosus or photosensitivity are predisposed to drug-induced or drug-exacerbated disease.

PMID: 11559217 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&...

Tweet